Floatz logo

Pyrotinib

Pancreatic Adenocarcinoma

Indaptus Therapeutics, IncSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

76 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Calcium folinate pentahydrate
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Capecitabine
Zhejiang University
Phase 4BB

View all 50 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →